



Lab Resource: Multiple Cell Lines

Generation of four iPSC lines from two siblings with a microdeletion at the *CNTN6* gene and intellectual disability



T.A. Shnaider^{a,*}, I.E. Pristyazhnyuk^a, A.G. Menzorov^{a,b}, N.M. Matveeva^a, T.V. Nikitina^c, A.A. Khabarova^a, N.A. Skryabin^c, A.A. Kashevarova^c, M.E. Lopatkina^c, L.P. Nazarenko^{c,d}, I.N. Lebedev^{c,d}, O.L. Serov^{a,b}

^a Institute of Cytology and Genetics, SB RAS, Novosibirsk, Russia

^b Novosibirsk State University, Novosibirsk, Russia

^c Research Institute of Medical Genetics, Tomsk NRMС, Tomsk, Russia

^d Siberian State Medical University, Tomsk, Russia

ABSTRACT

The human induced pluripotent stem cell (iPSC) lines, ICGi009-A, ICGi009-B, ICGi013-A and ICGi013-B, were generated from skin fibroblasts of two siblings with intellectual disability. Both patients were carriers of *CNTN6* gene microdeletion (Kashevarova et al., 2014). iPSC lines have normal karyotype, express pluripotency markers, are able to differentiate in vitro into derivatives of all three germ layers and represent a unique tool to study neurodevelopmental disorders.

| Resource table | | Inducible/constitutive system | N/A |
|--------------------------------------|--|-------------------------------|---|
| Unique stem cell lines identifier | ICGi009-A ICGi009-B ICGi013-A ICGi013-B | Date archived/stock date | September 2018 |
| Alternative names of stem cell lines | iTAF3-17, iTAF3del17 (ICGi009-A) iTAF3-37, iTAF3del37 (ICGi009-B) iTAF13-26, iTAF13del26 (ICGi013-A) iTAF13-27, iTAF13del27 (ICGi013-B) | Cell line repository/bank | Bioresource collection of the Research Institute of Medical Genetics, Tomsk NRMС, "Biobank of the population of Northern Eurasia"; Collective Center of ICG SB RAS "Collection of Pluripotent Human and Mammalian Cell Cultures for Biological and Biomedical Research" |
| Institution | Institute of Cytology and Genetics Siberian Branch of the Russian Academy of Sciences (ICG SB RAS), Novosibirsk, Russia | Ethical approval | Written informed consents were obtained from the patients. The study was approved by the Scientific Ethics Committee of Research Institute of Medical Genetics, Tomsk NRMС (protocol number 106/2017) |
| Contact information of distributor | Shnaider T.A., shnayder.t@yandex.ru | | |
| Type of cell lines | iPSC | | |
| Origin | Human | | |
| Cell Source | Fibroblasts | | |
| Clonality | Clonal | | |
| Method of reprogramming | lentivirus | | |
| Multiline rationale | Isogenic and same disease non-isogenic cell lines | | |
| Gene modification | Yes | | |
| Type of modification | Spontaneous mutation (<i>de novo</i>) | | |
| Associated disease | Intellectual disability | | |
| Gene/locus | arr[hg19]3p26.3(1197623 – 1492721) × 1.seq[hg19] del(3)(3p26.3)chr3:g.1158406-407T(19_22)_1568210del | | |
| Method of modification | N/A | | |
| Name of transgene or resistance | N/A | | |

1. Resource utility

Neurodevelopmental disorders represent a large group of diseases characterized by significantly impaired intellectual and cognitive functions. Derived iPSC lines can provide a great opportunity to investigate cellular and molecular mechanisms of mental retardation caused by *CNTN6* gene mutation

2. Resource details

Human skin fibroblasts TAF3del and TAF13del were derived from two siblings: 20-years old male and 18-years old female with intellectual disability and microdeletion of *CNTN6* gene, previously described by Kashevarova et al. (2014). Cells were reprogrammed with

* Corresponding author.

E-mail address: shnayder.t@yandex.ru (T.A. Shnaider).

<https://doi.org/10.1016/j.scr.2019.101591>

Received 2 July 2019; Received in revised form 10 September 2019; Accepted 17 September 2019

Available online 21 October 2019

1873-5061/ © 2019 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license

(<http://creativecommons.org/licenses/by/4.0/>).




Fig. 1. Characterization of human iPS cell lines ICGi009-A, ICGi009-B, ICGi013-A and ICGi013-B.

Table 1
Summary of lines.

| iPSC line names | Abbreviation in figures | Gender | Age | Ethnicity | Genotype of locus | Disease |
|-----------------|-------------------------|--------|-----|-----------|--|-------------------------|
| ICGi009-A | ICGi009-A | Male | 20 | Caucasian | arr[hg19]3p26.3(1197623-1492721) × 1.seq[hg19] del(3)(3p26.3) chr3:g.1158406-407T(19,22)_1568210del | Intellectual disability |
| ICGi009-B | ICGi009-B | Male | 20 | Caucasian | arr[hg19]3p26.3(1197623-1492721) × 1.seq[hg19] del(3)(3p26.3) chr3:g.1158406-407T(19,22)_1568210del | Intellectual disability |
| ICGi013-A | ICGi013-A | Female | 18 | Caucasian | arr[hg19]3p26.3(1197623-1492721) × 1.seq[hg19] del(3)(3p26.3)chr3:g.1158406-407T(19,22)_1568210del | Intellectual disability |
| ICGi013-B | ICGi013-B | Female | 18 | Caucasian | arr[hg19]3p26.3(1197623-1,492,721) × 1.seq[hg19] del(3)(3p26.3)chr3:g.1158406-407T(19,22)_1568210del | Intellectual disability |

lentiviral delivery of Yamanaka factors (*OCT3/4*, *SOX2*, *KLF4* and *c-MYC*). Generated iPSC lines (ICGi009-A, ICGi009-B, ICGi013-A and ICGi013-B) displayed typical morphology of human pluripotent stem cells both in feeder-dependent (data not shown) and feeder-free conditions (Fig. 1A) and expressed the typical pluripotent markers *OCT3/4*, *NANOG* and *TDGF* as shown by immunocytochemistry (Fig. 1B) and RT-PCR (Fig. 1D). All four iPSC lines demonstrated chromosomal stability and normal karyotype (Fig. 1C). One homologue of TAF13del chromosome 22 had prominent satellites (46, XX, 22ps+) as well as two iPSC lines which were produced from these fibroblasts. To prove pluripotency, ICGi009-A, ICGi009-B, ICGi013-A and ICGi013-B were spontaneously differentiated into embryoid bodies. RT-PCR revealed the presence of markers of all three germ layers: endoderm, mesoderm and ectoderm (Fig. 1E). Additionally, using the immunofluorescence staining of histone H3 tri-methylated at K27, enriched in transcriptionally silenced sex chromatin, we checked the status of X-chromosomes in TAF13del, ICGi013-A and ICGi013-B cell lines generated from female and showed the presence of two active X-chromosomes in both iPSC lines in comparison with one inactivated X-chromosome in fibroblasts (the red dot marked by the arrow on the Supplementary Fig. 1B). The STR profile of iPSC lines fully matched in pairs with that of the original TAF3del and TAF13del fibroblasts (loci analyzed: D1S1656, D2S441, D3S1358, D5S818, D7S820, D8S1179, D10S1248, D12S391, D13S317, D16S539, D18S51, D21S11, D22S1045, AMEL, CSF1PO, FGA, SE33, TH01, TPOX, and vWA). All iPSC lines were negative for Mycoplasma contamination (Supplementary Fig. 1C).

3. Materials and methods

3.1. Cell culture

Human fibroblasts TAF3del and TAF13del were derived from patients with 3p26.3 microdeletion and cultured in growth media (DMEM/F12 supplemented with 10% fetal bovine serum (FBS), 1% Pen Strep, 1% MEM NEAA(all from Thermo Fisher Scientific), 1% MEM Vitamin solution, 2 mM l-glutamine (both from Sigma-Aldrich) at 37 °C in 5% CO₂.

3.2. Reprogramming

To generate iPSCs lines from the patient's fibroblasts we used LeGO lentiviral vectors containing the human reprogramming transcription factors *OCT3/4*, *SOX2*, *C-MYC*, and *KLF4* (all vectors were kindly provided to us by Dr. Sergei L. Kiselev (Moscow, Russia)). The lentiviruses were produced in the Phoenix cell line using Lipofectamine 3000 (Thermo Fisher Scientific) according to the manufacturer's recommendations. Multiplicity of infection was estimated as 3 using GFP lentiviral vector LeGO-G2 (<https://www.addgene.org/25917/>). Reprogramming factors were delivered using the same vector with eGFP substituted by transcription factor coding sequences. It was assumed that MOI for OKSM factors was close to LeGO-G2 MOI. Briefly, human fibroblasts plated on the previous day (15,000 cells per cm²) were transduced with lentiviruses containing the four reprogramming transcription factors for two days (on the second day, the C-MYC lentivirus was omitted). Until day 10, the culture medium was changed daily with addition of 1 mM valproic acid (Sigma-Aldrich). On day 5, the transduced cells were seeded onto feeder cells (mitomycin C-treated CD-1 mouse embryonic fibroblasts) in iPSC medium (DMEM/F12 medium supplemented with 20% KnockOut Serum Replacement, 1% GlutaMAX™-I, 1% MEM NEAA, 1% Pen Strep, 10 ng/ml bFGF (all from Thermo Fisher Scientific) and 0.1 mM 2-mercaptoethanol (Helicon). On days 18–20, colonies with iPSC morphology were picked and expanded. All cell cultures were maintained at 37 °C in an atmosphere of 5% CO₂. iPSCs on feeder cells were expanded mechanically for several passages and then were adapted to feeder-free culture conditions: surface coating Matrigel®Matrix (Corning), enzymatic dissociation using Stem Pro

Table 2
Characterization and validation.

| Classification | Test | Result | Data |
|-------------------------------------|--|---|---|
| Morphology | Photography | Normal | Fig. 1 panel A |
| Phenotype | Qualitative analysis Immunocytochemistry and RT-PCR | Positive for <i>OCT3/4</i> , <i>NANOG</i> and expression of <i>OCT3/4</i> , <i>NANOG</i> and <i>TGDF1</i> | Fig. 1 panel B and E |
| | Quantitative analysis Immunocytochemistry | Assessed% of positive cells: ICGi009-A: <i>NANOG</i> – 94.3% (<i>n</i> = 282), <i>OCT3/4</i> – 95.5% (<i>n</i> = 356); ICGi009-B: <i>NANOG</i> – 98.4% (<i>n</i> = 252), <i>OCT3/4</i> – 94.1% (<i>n</i> = 102); ICGi013-A: <i>NANOG</i> – 97.4% (<i>n</i> = 193), <i>OCT3/4</i> – 96.8% (<i>n</i> = 249); ICGi013-B: <i>NANOG</i> – 96.6% (<i>n</i> = 262), <i>OCT3/4</i> – 98.5% (<i>n</i> = 204) | Fig. 1 panel B |
| Genotype | Karyotype (G-banding) and resolution | ICGi009-A: 46,XY ICGi009-B: 46,XY ICGi013-A: 46,XX, 22ps+; ICGi013-B: 46,XX, 22ps+; Resolution 450 | Fig. 1 panel C |
| Identity | STR analysis | Performed | Available with the authors |
| | | 20 sites were tested, 20/20 matched | Available with the authors |
| Mutation analysis (IF APPLICABLE) | Sequencing | Male: arr[hg19]3p26.3(1197623-1492721) × 1.seq[hg19] del(3)(3p26.3) chr3:g.1158406-407T(19,22),1568210del Female: arr[hg19]3p26.3(1197623-1492721) × 1.seq[hg19] del(3)(3p26.3)chr3:g.1158406-407T(19,22),1568210del | Fig. 1 panel D; Supplementary, Fig. 1 panel A |
| Microbiology and virology | Mycoplasma | Mycoplasma testing by PCR. Negative | Supplementary, Fig. 1 panel C |
| Differentiation potential | Embryoid body formation | Expression of the three germ layer markers in embryoid bodies: Endoderm (<i>SOX17</i> , <i>FOXA2</i> and <i>AFP</i>) Mesoderm (<i>FLK1</i> , <i>MSX1</i> and <i>TBXT</i>) Ectoderm (<i>PAX6</i> and <i>MAP2</i>) | Fig. 1 panel F |
| Donor screening (OPTIONAL) | HIV 1 + 2 Hepatitis B, Hepatitis C | N/A | N/A |
| Genotype additional info (OPTIONAL) | Blood group genotyping HLA tissue typing | N/A N/A | N/A N/A |

Accutase (Thermo Fisher Scientific) and cultivation in mTeSRTM1 medium (STEMCELL Technologies). iPSCs were split every 7–10 days in ratio 1:3–1:4 under feeder-dependent conditions and every 6–10 days in ratio 1:4–1:6 under feeder-free condition. After splitting iPSCs either mechanically or enzymatically ROCK inhibitor Y27632 (Abcam) was added in concentration 10 μM to increase cell viability.

3.3. Immunocytochemistry

The iPSCs were fixed in 3% paraformaldehyde for 20 min at room temperature (RT), blocking of unspecific sites was achieved by incubation with blocking buffer: 5% FBS (Thermo Fisher Scientific) and

2% BSA (Sigma-Aldrich) in the presence of 0.1% Triton-X100 (Sigma-Aldrich) for 20 min at RT. Primary antibodies were diluted in blocking buffer and incubated overnight at 4 °C. Secondary antibodies were diluted in PBS and incubated for 2 h at RT (Table 3). Nuclei were stained with DAPI (Sigma-Aldrich) and immunofluorescence was visualized under confocal fluorescence microscope LSM 780 NLO (Zeiss) with ZEN software (Zeiss).

3.4. RNA isolation and RT-PCR

To confirm expression of pluripotency markers in iPSCs and differentiation markers in generated embryoid bodies, RT-PCR with

Table 3
Reagents details.

| Antibodies used for immunocytochemistry | | | |
|---|--|---|--|
| | Antibody | Dilution | Company Cat # and RRID |
| Pluripotency markers | Rabbit anti- <i>OCT4</i> | 1:200 | Abcam Cat# 19857, RRID: AB_445175 |
| Pluripotency markers | Rabbit anti- <i>NANOG</i> | 1:100 | Abcam Cat# 21624, RRID: AB_446437 |
| X-inactivation marker | Mouse anti-Histone H3 (tri methyl K27) | 1: 200 | Abcam Cat# 6002, RRID:AB_305237 |
| Secondary antibodies | Alexa Fluor 488 Goat Anti-Mouse IgG | 1:500 | Life technologies Cat# A-11029, RRID:AB_138404 |
| Secondary antibodies | Alexa Fluor 546 Goat Anti- Rabbit IgG | 1:500 | Life technologies Cat# A-11010, RRID:AB_143156 |
| Primers | | | |
| | Target, size | Forward/Reverse primer (5'–3') | |
| House-keeping genes | GAPDH, 153 bp | GTGGACCTGACCTGCCGTCT/GGAGGAGTGGGTGTCGCTGT | |
| Pluripotency markers | <i>NANOG</i> , 110 bp | AAAGAATCTTACCTATGCC/GAAGGAAGAGGAGAGACAGT | |
| Pluripotency markers | <i>OCT3/4</i> , 127 bp | CTGGGTGATCCTCGGACCT/CACAGAACTCATACGGCGGG | |
| Pluripotency markers | <i>TGDF1</i> , 139 bp | TCCTTCTACGGACGGAACTG/AGAAATGCCTGAGGAAAGCA | |
| Differentiation markers | <i>AFP</i> , 136 bp | AAATGCGTTTCTCGTTGCTT/GCCACAGGCCAATAGTTTGT | |
| Differentiation markers | <i>FKL1</i> , 131 bp | TGATCGGAAATGACACTGGA/CACGACTCCATGTTGGTTCAC | |
| Differentiation markers | <i>FOXA2</i> , 122 bp | GGAGCGGTGAAGATGGAA/TACGTGTTTCATGCCGTTTCAT | |
| Differentiation markers | <i>MAP2</i> , 212 bp | CAGGTGGCGGACGTTGAAAATTGAGAGTG/CACGCTGGATCTGCCTGGGACTGTG | |
| Differentiation markers | <i>MSX1</i> , 307 bp | CGAGAGGACCCCGTGGATGCAGAG/GGCGGCCATCTTCAGCTTCTCCAG | |
| Differentiation markers | <i>PAX6</i> , 100 bp | GTCCATCTTGTCTGGGAAA/TAGCCAGGTTGCGAAGAAGT | |
| Differentiation markers | <i>SOX17</i> , 102 bp | CTCTGCCTCCTCCAGAA/CAGAATCCAGACCTGCACAA | |
| Differentiation markers | <i>TBXT</i> , 112 bp | AATTGGGTCCAGCCTTGGAAAT/CGTTGCTCACAGACCACA | |
| Primers for sequencing | Region contained deletion, ~850 bp | TCAGTGGACAACATTTGTATAGGC/TGTGAAGTTGGCAAACACCAT | |

primers specific for pluripotency genes (Table 3) was performed. Total RNA was isolated with TRI Reagent® according to the manufacturer's protocol (Sigma Aldrich). To eliminate possible sample contamination with genomic DNA RNA was treated with DNase I (Thermo Fisher Scientific) according to manufacturer's instructions under following conditions: incubation for 30 min at 37 °C and inactivation for 10 min at 65 °C. RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific) was used for reverse transcription with random hexamer primers according to the manufacturer's protocol. PCR was performed with T100 ThermoCycler (BIO-RAD) and Taq MasterMix (IMCB SB RAS, Russia) under the following conditions: 95 °C for 5 min followed by 35 cycles of 95 °C for 1 s, 55 °C for 15 s and 72 °C for 30 s, then 72 °C for 5 min and 12 °C for holding.

3.5. *In vitro* differentiation

Embryoid bodies were produced according to previously published protocol (Bock et al., 2011). Primers for RT-PCR were taken from Huangfu et al. (2008).

3.6. Karyotyping

iPSCs were karyotyped at passage 7, 8. Karyotype analysis was performed using conventional GTG banding techniques according to standard cytogenetic protocols (Prokhorovich et al., 2007) based on the International System for Human Cytogenetic Nomenclature (2016). We have analyzed at least 50 metaphases for each iPSC line (450-band resolution).

3.7. Mycoplasma contamination detection

The absence of mycoplasma contamination was confirmed by PCR using primers from Pisal et al. (2016). Genomic DNA from iPSCs was isolated by phenol/chloroform extraction. PCR was performed with T100 ThermoCycler (BIO-RAD) and Taq MasterMix (IMCB SB RAS, Russia) under the following conditions: 95 °C for 5 min followed by 35 cycles of 95 °C for 20 s, 55 °C for 15 s and 72 °C for 30 s, then 72 °C for 5 min and 12 °C for holding.

3.8. STR analysis

Genomic DNA extracted by phenol/chloroform from TAF3del and

TAF13del fibroblast and their derivative iPSC lines ICGi009-A, ICGi009-B, ICGi013-A and ICGi013-B were authenticated by STR analysis by biotechnological company Gordiz (<http://gordiz.ru/>)

Acknowledgments

This study was supported by the Russian Foundation for Basic Research (grant no. 19-29-04067) and Russian Science Foundation (grant no. 14-15-00772). Microscopic analysis was carried out at the Multiple-access Center for Microscopy of Biological Subjects (Institute of Cytology and Genetics, Novosibirsk, Russia). We are grateful to the family for participation in the study. We thank Dr Veniamin S. Fishman and Alexander V. Smirnov for valuable advice.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at [doi:10.1016/j.scr.2019.101591](https://doi.org/10.1016/j.scr.2019.101591).

References

- Bock, C., Kiskinis, E., Verstappen, G., Gu, H., Boulting, G., Smith, Z.D., Ziller, M., Croft, G.F., Amoroso, M.W., Oakley, D.H., Gnirke, A., Eggan, K., Meissner, A., 2011. Reference maps of human ES and iPSC cell variation enable high-throughput characterization of pluripotent cell lines. *Cell* 144, 439–452. <https://doi.org/10.1016/j.cell.2010.12.032>.
- Huangfu, D., Osafune, K., R.Maehr, W.Guo, Eijkelenboom, A., Chen, S., Muhlestein, W., Melton, D.A., 2008. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. *Nat Biotechnol.* 26 (11), 1269–1275. <https://doi.org/10.1038/nbt.1502>.
- A.A. Kashevarova, L.P. Nazarenko, S. Schultz-Pedersen, N.A. Skryabin, O.A. Salyukova, N. N. Chechetkina, E.N. Tolmacheva, A.A. Rudko, P. Magini, C. Graziano, G. Romeo, S. Joss, Z. Tümer, I.N. Lebedev. Single gene microdeletions and microduplication of 3p26.3 in three unrelated families: CNTN6 as a new candidate gene for intellectual disability. *Mol Cytogenet.*, 7(1) (2014):97, 10.1186/s13039-014-0097-0.
- Pisal, R.V., Hrebíková, H., Chvátalová, J., Kunke, D., Filip, S., 2016. J. mokřý Detection of Mycoplasma Contamination Directly from Culture Supernatant Using Polymerase Chain Reaction. *Folia Biol (Praha)*. 62 (5), 203–206.
- Prokhorovich, M.A., Lagarkova, M.A., Shilov, A.G., Karamysheva, T.V., Kiselyov, S.L., 2007. N.B. Rubtsov Cultures of hESM human embryonic stem cells: chromosomal aberrations and karyotype stability. *Bull. Exp. Biol. Med.* 144 (1), 126–129. <https://doi.org/10.1007/s10517-007-0271-z>.